BioXcel Therapeutics (BTAI) Non-Current Debt (2022 - 2026)

BioXcel Therapeutics' Non-Current Debt history runs 5 years deep, the most recent figure standing at $77.9 million for Q1 2026.

• In Q1 2026, Non-Current Debt fell 22.08% year-over-year to $77.9 million; the TTM figure through Mar 2026 stood at $77.9 million (down 22.08% YoY), while the FY2025 annual figure was $84.7 million, down 17.41% from the prior year.
• Non-Current Debt was $77.9 million for Q1 2026 at BioXcel Therapeutics, down from $84.7 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $104.4 million in Q3 2024 to a low of $61.1 million in Q2 2022.
• Historically, Non-Current Debt has averaged $93.8 million across 5 years, with a median of $97.2 million in 2023.
• The sharpest annual moves came in 2023 and 2026: Non-Current Debt surged 58.57% in 2023, then retreated 22.08% in 2026.
• A 5-year view of Non-Current Debt shows it stood at $93.1 million in 2022, then advanced by 8.11% to $100.6 million in 2023, then increased by 1.9% to $102.5 million in 2024, then fell by 17.41% to $84.7 million in 2025, then dropped by 8.04% to $77.9 million in 2026.
• The last three Non-Current Debt figures came in at $77.9 million (Q1 2026), $84.7 million (Q4 2025), and $92.3 million (Q3 2025), per Business Quant data.